Multiplexed Optical Imaging of Tumor-Directed Nanoparticles: A Review of Imaging Systems and Approaches

Wang, Yu “Winston”; Reder, Nicholas P.; Kang, Soyoung; Glaser, Adam K.; Liu, Jonathan

doi:10.7150/ntno.21136

Cited by 58 publications

(40 citation statements)

References 166 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The broad absorption spectra and large stokes shifts of quantum dots allow simultaneous imaging of multiple types of quantum dots with single wavelength excitation. Quantum dots are also often coupled to a biomolecule for targeted imaging [ 84 ]. Lead sulfide quantum dots with 1100 nm emission peaks can be used in NIR fluorescence imaging of cerebral venous thrombosis.…”

Section: Medical Imagingmentioning

confidence: 99%

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

2020

View full text Add to dashboard Cite

Nanomaterials, such as nanoparticles, nanorods, nanosphere, nanoshells, and nanostars, are very commonly used in biomedical imaging and cancer therapy. They make excellent drug carriers, imaging contrast agents, photothermal agents, photoacoustic agents, and radiation dose enhancers, among other applications. Recent advances in nanotechnology have led to the use of nanomaterials in many areas of functional imaging, cancer therapy, and synergistic combinational platforms. This review will systematically explore various applications of nanomaterials in biomedical imaging and cancer therapy. The medical imaging modalities include magnetic resonance imaging, computed tomography, positron emission tomography, single photon emission computerized tomography, optical imaging, ultrasound, and photoacoustic imaging. Various cancer therapeutic methods will also be included, including photothermal therapy, photodynamic therapy, chemotherapy, and immunotherapy. This review also covers theranostics, which use the same agent in diagnosis and therapy. This includes recent advances in multimodality imaging, image-guided therapy, and combination therapy. We found that the continuous advances of synthesis and design of novel nanomaterials will enhance the future development of medical imaging and cancer therapy. However, more resources should be available to examine side effects and cell toxicity when using nanomaterials in humans.

show abstract

Section: Medical Imagingmentioning

confidence: 99%

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

2020

View full text Add to dashboard Cite

show abstract

“…Imaging probes are being developed for use as directly‐visualized agents, include intraoperative imaging tools to help localize tumors with or without the use of a traditional imaging platform such as CT, MRI, PET, and so on. Examples include the use of fluorescent probes, Raman‐scattering (SERS), polymer dots and quantum dots (QD) . For example, a liposomal encapsulated iodohexal (an iodinated contrast agent) was conjugated to an ICG, which allowed both preoperative and intraoperative tumor localization in rabbit lung cancer models.…”

Section: Nanoprobes For Cancer Multimodal Imagingmentioning

confidence: 99%

Recent advances in the development of nanoparticles for multimodality imaging and therapy of cancer

Liu

Anderson

Lan

et al. 2019

Medicinal Research Reviews

View full text Add to dashboard Cite

This review explores recent work directed toward the development of nanoparticles (NPs) for multimodality cancer imaging and targeted cancer therapy. In the growing era of precision medicine, theranostics, or the combined use of targeted molecular probes in diagnosing and treating diseases is playing a particularly powerful role. There is a growing interest, particularly over the past few decades, in the use of NPs as theranostic tools due to their excellent performance in receptor target specificity and reduction in off-target effects when used as therapeutic agents. This review discusses recent advances, as well as the advantages and challenges of the application of NPs in cancer imaging and therapy.

show abstract

“…SERS is a vibrational spectroscopic technique for probing molecules on or near the nanoscale surface of metallic substrates, which enables a rapid, sensitive and non-destructive detection of the target molecules with characteristic spectra via localized surface plasmon resonances [21][22][23][24]. Recently, SERS nanotags as a new class of label have demonstrated unique and attractive applications in biological labelling with key advantages including ultra-sensitivity (down to single molecule under certain conditions), suitability for multiplexing due to the narrow width of vibrational Raman bands, quantification based on spectral intensities, high photostability, minimal autofluorescence from biological specimens via red to near-infrared (NIR) laser excitation, and the requirement for only single laser source for excitation [21,22,[25][26][27]. The multiplexing capability is potentially very useful for screening multiple mutations from limited samples, such as ctDNA.…”

Section: Introductionmentioning

confidence: 99%

Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay

Lyu¹,

Rajendran²,

Diefenbach³

et al. 2020

Nanotheranostics

View full text Add to dashboard Cite

Molecular diagnostic testing of KRAS and BRAF mutations has become critical in the management of colorectal cancer (CRC) patients. Some progress has been made in liquid biopsy detection of mutations in circulating tumor DNA (ctDNA), which is a fraction of circulating cell-free DNA (cfDNA), but slow analysis for DNA sequencing methods has limited rapid diagnostics. Other methods such as quantitative PCR and more recently, droplet digital PCR (ddPCR), have limitations in multiplexed capacity and the need for expensive specialized equipment. Hence, a robust, rapid and facile strategy is needed for detecting multiple ctDNA mutations to improve the management of CRC patients. To address this significant problem, herein, we propose a new application of multiplex PCR/SERS (surface-enhanced Raman scattering) assay for the detection of ctDNA in CRC, in a fast and non-invasive manner to diagnose and stratify patients for effective treatment. Methods: To discriminate ctDNA mutations from wild-type cfDNA, allele-specific primers were designed for the amplification of three clinically important DNA point mutations in CRC including KRAS G12V, KRAS G13D and BRAF V600E. Surface-enhanced Raman scattering (SERS) nanotags were labelled with a short and specific sequence of oligonucleotide, which can hybridize with the corresponding PCR amplicons. The PCR/SERS assay was implemented by firstly amplifying the multiple mutations, followed by binding with multicolor SERS nanotags specific to each mutation, and subsequent enrichment with magnetic beads. The mutation status was evaluated using a portable Raman spectrometer where the fingerprint spectral peaks of the corresponding SERS nanotags indicate the presence of the mutant targets. The method was then applied to detect ctDNA from CRC patients under a blinded test, the results were further validated by ddPCR. Results: The PCR/SERS strategy showed high specificity and sensitivity for genotyping CRC cell lines and plasma ctDNA, where as few as 0.1% mutant alleles could be detected from a background of abundant wild-type cfDNA. The blinded test using 9 samples from advanced CRC patients by PCR/SERS assay was validated with ddPCR and showed good consistency with pathology testing results. Conclusions: With ddPCR-like sensitivity yet at the convenience of standard PCR, the proposed assay shows great potential in sensitive detection of multiple ctDNA mutations for clinical decision-making.

show abstract

Multiplexed Optical Imaging of Tumor-Directed Nanoparticles: A Review of Imaging Systems and Approaches

Cited by 58 publications

References 166 publications

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

Application of Nanomaterials in Biomedical Imaging and Cancer Therapy

Recent advances in the development of nanoparticles for multimodality imaging and therapy of cancer

Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay

Contact Info

Product

Resources

About